Literature DB >> 24293164

Invariant chain as a vehicle to load antigenic peptides on human MHC class I for cytotoxic T-cell activation.

Sébastien Wälchli1, Shraddha Kumari, Lars-Egil Fallang, Kine M K Sand, Weiwen Yang, Ole J B Landsverk, Oddmund Bakke, Johanna Olweus, Tone F Gregers.   

Abstract

Protective T-cell responses depend on efficient presentation of antigen (Ag) in the context of major histocompatibility complex class I (MHCI) and class II (MHCII) molecules. Invariant chain (Ii) serves as a chaperone for MHCII molecules and mediates trafficking to the endosomal pathway. The genetic exchange of the class II-associated Ii peptide (CLIP) with antigenic peptides has proven efficient for loading of MHCII and activation of specific CD4(+) T cells. Here, we investigated if Ii could similarly activate human CD8(+) T cells when used as a vehicle for cytotoxic T-cell (CTL) epitopes. The results show that wild type Ii, and Ii in which CLIP was replaced by known CTL epitopes from the cancer targets MART-1 or CD20, coprecipitated with HLA-A*02:01 and mediated colocalization in the endosomal pathway. Furthermore, HLA-A*02:01-positive cells expressing CLIP-replaced Ii efficiently activated Ag-specific CD8(+) T cells in a TAP- and proteasome-independent manner. Finally, dendritic cells transfected with mRNA encoding IiMART-1 or IiCD20 primed naïve CD8(+) T cells. The results show that Ii carrying antigenic peptides in the CLIP region can promote efficient presentation of the epitopes to CTLs independently of the classical MHCI peptide loading machinery, facilitating novel vaccination strategies against cancer.
© 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Antigen presentation/processing; CD8+ T cells; MHC; Vaccination

Mesh:

Substances:

Year:  2013        PMID: 24293164     DOI: 10.1002/eji.201343671

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  8 in total

Review 1.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

2.  Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses.

Authors:  Yong Chan Kim; Ai-Hong Zhang; Yan Su; Sadiye Amcaoglu Rieder; Robert J Rossi; Ruth A Ettinger; Kathleen P Pratt; Ethan M Shevach; David W Scott
Journal:  Blood       Date:  2014-12-10       Impact factor: 22.113

3.  A computational docking study on the pH dependence of peptide binding to HLA-B27 sub-types differentially associated with ankylosing spondylitis.

Authors:  Onur Serçinoğlu; Gülin Özcan; Zeynep Kutlu Kabaş; Pemra Ozbek
Journal:  J Comput Aided Mol Des       Date:  2016-08-09       Impact factor: 3.686

4.  A TCR-based Chimeric Antigen Receptor.

Authors:  Even Walseng; Hakan Köksal; Ibrahim M Sektioglu; Anne Fåne; Gjertrud Skorstad; Gunnar Kvalheim; Gustav Gaudernack; Else Marit Inderberg; Sébastien Wälchli
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

5.  CD74 regulates complexity of tumor cell HLA class II peptidome in brain metastasis and is a positive prognostic marker for patient survival.

Authors:  P S Zeiner; J Zinke; D J Kowalewski; S Bernatz; J Tichy; M W Ronellenfitsch; F Thorsen; A Berger; M T Forster; A Muller; J P Steinbach; R Beschorner; J Wischhusen; H M Kvasnicka; K H Plate; S Stefanović; B Weide; M Mittelbronn; P N Harter
Journal:  Acta Neuropathol Commun       Date:  2018-03-01       Impact factor: 7.801

6.  Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.

Authors:  Nadia Mensali; Amalie Grenov; Niladri Bhusan Pati; Pierre Dillard; Marit Renée Myhre; Gustav Gaudernack; Gunnar Kvalheim; Else Marit Inderberg; Oddmund Bakke; Sébastien Wälchli
Journal:  Oncoimmunology       Date:  2019-01-11       Impact factor: 8.110

Review 7.  Cysteine Cathepsins in Tumor-Associated Immune Cells.

Authors:  Tanja Jakoš; Anja Pišlar; Anahid Jewett; Janko Kos
Journal:  Front Immunol       Date:  2019-08-28       Impact factor: 7.561

8.  Development of a Molecular Adjuvant to Enhance Antigen-Specific CD8+ T Cell Responses.

Authors:  Benedict R Halbroth; Sarah Sebastian; Hazel C Poyntz; Migena Bregu; Matthew G Cottingham; Adrian V S Hill; Alexandra J Spencer
Journal:  Sci Rep       Date:  2018-10-09       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.